bTrCP and HOS are closely related F-box proteins, which play key roles in ubiquitination and degradation of b-catenin and IkB through associating with those phosphorylated substrates and recruiting SCF E3 ubiquitin ligase. Here we report that activation of Wnt/b-catenin signal transduction pathway elevates bTrCP levels but inhibits expression of HOS in 293T cells. Similar disparity is likely to exist in human colorectal tumors. In the NIH3T3 cells, which express HOS, but not bTrCP, Wnt/b-catenin signaling leads to inhibition of HOS promoter activity and NF-kB-driven transcription as well as to stabilization of b-catenin. These results indicate that expression and activities of HOS are negatively regulated by Wnt/b-catenin pathway.
Ubiquitin-mediated degradation of key regulatory cellular proteins often plays an important role in signal transduction (reviewed in Fuchs et al., 1998) . Wnt/bcatenin pathway represents an example for such regulation. In the absence of Wnt signaling or oncogenic mutations in APC or b-catenin, b-catenin levels remain low due to constitutive phosphorylation by glycogen synthase kinase 3b (GSK3b) and ubiquitin-mediated proteolysis of phosphorylated b-catenin. Activation of Wnt/b-catenin signaling pathway results in stabilization of cytoplasmic b-catenin. Accumulation and translocation of b-catenin to nuclei up regulates Tcf/Lef-dependent transcription and induces serumindependent cellular proliferation (reviewed in Polakis, 1999) .
Regulation of levels and activities of speci®c E3 ubiquitin protein ligases which target substrates for ubiquitination often represent a rate limiting factor for ubiquitination of speci®c cellular modulators (Joazeiro and Weissman, 2000) . Phosphorylation-dependent ubiquitination and degradation of b-catenin and an inhibitor of transcription factor NF-kB (IkB) is mediated by SCF HOS/bTrCP E3 ubiquitin ligase (reviewed in Maniatis, 1999) . Whereas speci®c phosphorylation of a DS(PO 3 )GcXS(PO 3 ) motif in IkB (by IkB kinase) and in b-catenin (by GSK3b) is indispensable, the activity of the ligase is also essential for ubiquitination of those substrates. SCF HOS/bTrCP E3 ubiquitin ligase consists of one of the two closely related F-box proteins (bTrCP/Fbw1a and HOS/bTrCP2/Fbw1b) (Cenciarelli et al., 1999; Winston et al., 1999a) as well as of Skp1, Cull and ROC1/Rbx1/Hrt1 proteins (reviewed in Deshaies, 1999) .
Over-expression of HOS (Fuchs et al., 1999) or bTrCP (Kroll et al., 1999) results in the induction of SCF HOS/bTrCP E3 ubiquitin ligase activities. Conversely, the function of bTrCP/HOS can be readily inhibited by expression of a pseudo-substrate (Vpu; Bour et al., 2001) or the substrate-mimicking phosphopeptides (Yaron et al., 1997) or dominant negative constructs lacking F-box (Fuchs et al., 1999; Hart et al., 1999; Kitagawa et al., 1999; Kroll et al., 1999; Latres et al., 1999; Spencer et al., 1999; Suzuki et al., 1999; Winston et al., 1999b; Yaron et al., 1998) . These observations suggest that regulation of bTrCP and HOS levels will contribute to the outcome of Wnt/b-catenin/Tcf and NF-kB signaling pathways.
We have recently found that the endogenous levels of bTrCP can be up regulated in some cells by the activation of the Wnt/b-catenin/Tcf signaling pathway, resulting in the activation of NF-kB-dependent transcription (Spiegelman et al., 2000) . Since the pro®les of bTrCP and HOS expression may dier between various tissues and cell lines (Saitoh and Katoh, 2001; Spiegelman et al., 2001) , in this study, we investigated the eect of the Wnt/b-catenin signaling on the expression and activities of HOS.
Forced expression of Wnt2 or constitutively active and stable mutant of b-catenin (b-catenin S33Y ) in 293T human embryo kidney cells resulted in a robust increase in steady state levels of bTrCP mRNA (Figure 1a, upper panel) . This result is in agreement with our previous observations (Spiegelman et al., 2000) . When the same Northern blot membrane was re-hybridized with HOS-speci®c probe, we observed a 4 ± 5-fold decrease in the levels of HOS message in the cells with activated Wnt/b-catenin signaling pathway (Figure 1a , middle panel). These data suggest that HOS and bTrCP, although being closely related proteins and exerting apparently similar functions, are dierently regulated by the same signal transduction pathway.
We have previously reported the genomic organization of HOS gene (also named bTrCP2) and isolated the promoter region of HOS (Koike et al., 2000) . Reporter assays with the luciferase expressed under control of 2.1 kb fragment of HOS promoter in NIH 3T3 mouse ®broblasts demonstrated that co-transfection of constitutively active b-catenin S33Y mutant led to a dose-dependent inhibition in the transcriptional activities of HOS promoter (Figure 1b, black bars) . This decrease in reporter activity was not found when a p21 CIP/WAF promotor-driven luciferase construct was used (Figure 1b, gray bars) . This result indicates that eect of b-catenin S33Y mutant was unlikely caused by direct inhibition of luciferase enzyme per se. These data suggest that activation of Wnt/b-catenin signaling pathway inhibits the transcriptional activity of HOS promoter.
In order to test whether the expression of HOS is inhibited by Wnt/b-catenin signaling in relevant pathologic settings, we looked into primary human cancers. Activation of Wnt/b-catenin signaling pathway is a hallmark of colon carcinogenesis (reviewed in Polakis et al., 1999) . Accumulation of bTrCP mRNA largely coincides with stabilization of b-catenin in the colorectal tumors and can be used as an indicator of the activated Wnt/b-catenin signaling (Spiegelman et al., 2000) . We sought to investigate whether HOS levels are decreased under these pathologic conditions by analysing the expression of HOS in cDNA specimens from eleven primary colon cancer patients by dot blot using the Matched Tumor/Normal Expression Array membrane (Clontech). We found that in eight cases (Figure 1c, No. 2, 3, 4, 5, 6, 7, 9, 11 ) the levels of bTrCP were increased in cDNA from tumor tissues compared to the matching apparently normal ones. We also observed that the levels of HOS are decreased in six out of those eight cases (Figure 1c, No. 2, 3, 4, 5, 7, 11) . These data indicating the existence of an inverse correlation between bTrCP and HOS levels upon activation of Wnt/b-catenin signaling are in agreement with our results obtained in the transfection experiments ( Figure 1a ). Our ®ndings indicate that expres- Since HOS protein itself undergoes rapid proteasome-dependent degradation (Fuchs et al., 1999 and data not shown), a decrease in its mRNA levels will likely result in a decrease in the levels of HOS protein.
In order to test this assumption we have produced speci®c rabbit polyclonal antibodies against N-terminus derived (HOS-N) and C-terminus derived (HOS-C) peptide epitopes (see legend to Figure 2a for details) . Immunoprecipitation of in vitro translated HOS and bTrCP proteins demonstrated that HOS-N antibody recognized speci®cally HOS whereas HOS-C reacts with both proteins (Figure 2a) . We have used HOSspeci®c antibody for analysis of endogenous HOS levels in NIH3T3 cells by immunoprecipitation followed by immunoblot analysis. Transfection of those cells with b-catenin S33Y expression construct led to a striking decrease in the levels of HOS protein ( Figure  2b ). Similar results were observed in 293T cells (data not shown). These ®ndings suggest that activation of Wnt/b-catenin signaling decreases the expression of HOS protein.
Induction of Wnt/b-catenin pathway in the cells, which express bTrCP (e.g., 293T), leads to an enhanced activity of SCF bTrCP E3 ubiquitin ligase due to a robust bTrCP accumulation (Spiegelman et al., 2000) . On the contrary, in the cells, which express only HOS but not bTrCP (e.g., NIH3T3; Spiegelman et al., 2001 and data not shown), the inhibition of this ubiquitin ligase activity due to a decrease in HOS expression is expected. Such an inhibition is assumed to confer stabilization of b-catenin and IkB. To test this hypothesis, we ®rst analysed the degradation of cytoplasmic b-catenin under conditions of forced expression of deletion mutant of b-catenin (b-catenin DN ), which is capable of trans-activating Tcf without inhibiting GSK3b activities (Munemitsu et al., 1996) . Co-expression of b-catenin DN mutant with the wild type b-catenin in NIH3T3 cells resulted in a remarkable stabilization of the wild type protein (Figure 3a) . Indeed, this result is expectedly an opposite of the one obtained in 293T cells, which express bTrCP (Spiegelman et al., 2000) . This ®nding suggests that the activation of b-catenin/Tcf signaling prevents degradation of b-catenin, most likely due to a decrease in HOS levels.
Stabilization of b-catenin is expected to up regulate Tcf-dependent transcription. Expression of stable bcatenin S33Y mutant remarkably up regulated the activity of Tcf-driven reporter (TOP-Flash, Figure 3b , white bars) but not the activity of the Tcf-reporter with mutated Tcf motifs (FOP-Flash, Figure 3b , black bars) in NIH3T3 cells. Co-expression of the dominant negative Tcf4 (which is capable of occupying the Tcf/ Lef DNA motifs but cannot interact with b-catenin Morin et al., 1997) almost abrogated the eect of b-catenin S33Y on TOP-Flash activity, whereas over-expression of HOS resulted in a moderate decrease in Tcf-driven transcription. It is known that HOS does not recognize phosphorylationde®cient b-catenin S33Y mutant and, therefore, does not inhibit the eect of b-catenin S33Y on Tcf-driven transcription (Fuchs et al., 1999) . Thus we can attribute the impact of HOS over-expression to its eect on the degradation of endogenous wild type bcatenin, which (in the absence of exogenous HOS) accumulates in b-catenin S33Y -expressing cells due to an inhibition of endogenous HOS and contributes to the overall output of Tcf-dependent transcription. These ®ndings further suggest that inhibition of HOS (1.5 and 3.0 mg) and Tcf4 (1 mg) as indicated. Total amount of transfected DNA (4 mg) was equilibrated by addition of pCDNA3 plasmid. Twenty-four hours later the cells were harvested and the cell lysates were prepared and 1 mg of whole cell extracts were immunoprecipitated by C-HOS antibody (1 mg/mg lysate). The immunoprecipitated proteins were separated by 10% SDS ± PAGE, transferred onto nitrocellulose membrane and analysed by immunoblotting with N-HOS antibody (1 mg/ml). A representative ®gure of two independent experiments is shown expression and activities plays an important role in the regulation of Wnt/b-catenin pathway.
To investigate whether activation of Wnt/b-catenin/ Tcf pathway will inhibit NF-kB signaling in the cells, which express HOS (but not bTrCP), we have assessed the transcriptional activities of NF-kB by luciferase readout assay. These experiments showed that expression of stable active b-catenin S33Y mutant noticeably decreased the activity of the NF-kB-driven luciferase reporter in NIH3T3 cells (Figure 3c , black bars). This inhibition was apparently NF-kB-speci®c because it was not observed with the luciferase reporters driven by either p21 promoter (Figure 3c, white bars) or a pentamer of TPA-responsive elements (Figure 3c , gray bars). Inhibition of NF-kB activity was partially alleviated by co-expression of HOS. These data suggest that Wnt/b-catenin pathway may inhibit NF-kB signaling via decrease in endogenous HOS expression.
Our data indicate that activation of Wnt/b-catenin signaling results in the inhibition of HOS expression. In cells, that express HOS but not bTrCP, down regulation of HOS expression leads to further ampli®cation of b-catenin's input via stabilization of endogenous b-catenin and to inhibition of NF-kB signaling (presumably by stabilization of IkB). In such cells, acceleration of cell proliferation may not result in the cell transformation, since the latter requires NF-kB activities (Finco et al., 1997; Reuther et al., 1998) . Indeed, although expression of Wnt-1 and Wnt-2 induced growth alterations in NIH3T3 ®broblasts, they did not transform these cells (Ba®co et al., 1998) . It is conceivable that, in the process of cell transformation, down regulation of HOS by Wnt/bcatenin/Tcf pathway may impose a selective pressure for the subsequent activation of NF-kB. One way this can be achieved is by the restoration of HOS levels in response to another mutational or epigenetic event. Indeed, our preliminary results indicate that HOS levels are induced by mitogens treatment or expression of v-Ras oncogene (V Spiegelman et al., unpublished data). The importance of maintaining the levels of HOS in the cells lacking bTrCP expression is underscored by the notion that bTrCP/HOS may regulate the ubiquitination and degradation of substrates other than b-catenin and IkB (e.g., ATF4, (Lassot et al., 2001) ).
Our data suggest that, despite structural and functional similarity between bTrCP and HOS, those two F-box proteins are regulated by Wnt/b-catenin pathway in an entirely opposite manner. These dierences in the regulation may determine alternative responses to signal transduction events, depending on which of those F-box proteins are expressed in these very cells. 
